A Single Arm Pilot Study to Evaluate the Safety, Feasibility, and Dose Ranging of Splenic Nerve Stimulation in Patients with Rheumatoid Arthritis Using a Novel Implantable Device
This single-arm pilot study demonstrated that laparoscopic implantation of a novel device for splenic nerve stimulation in patients with refractory rheumatoid arthritis was feasible and safe, with preliminary evidence suggesting potential reductions in disease activity and inflammatory biomarkers in some participants.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Rheumatoid arthritis is a condition where the body's immune system mistakenly attacks its own joints, causing pain, swelling, and stiffness. For decades, doctors have treated this by using powerful drugs to calm the immune system down. While these medicines help many people, a significant number of patients do not respond well to them, or they cannot tolerate the side effects. These individuals are often described as having "difficult-to-treat" disease, leaving them in a state of chronic pain and disability with few options left. In recent years, scientists have begun exploring a different approach: instead of using chemicals to stop inflammation, they are using electricity to talk to the nerves that control the immune system. This field, known as neuromodulation, relies on the fact that the body has a built-in network of nerves that can turn inflammation up or down. One specific nerve, the splenic nerve, acts as a direct line to the spleen, an organ that plays a major role in managing the body's inflammatory response. By sending gentle electrical signals to this nerve, researchers hope to switch off the immune system's overactive state without the need for heavy medication.
A team of researchers recently took this concept from the laboratory to the operating room to test it in humans. They conducted a small, early-stage study involving five patients who had severe rheumatoid arthritis that had not improved with standard treatments. The goal was not to prove that the treatment worked for everyone, but simply to see if it was safe to implant a small electronic device and if the body could handle the electrical stimulation over time. The device, which looks like a small pacemaker, was surgically placed inside the abdomen using a minimally invasive technique. Once in place, it was programmed to send short bursts of electricity to the splenic nerve several times a day. The researchers monitored the patients closely for safety, checking for any pain, infection, or unexpected changes in heart rhythm, while also tracking how their arthritis symptoms changed.
The results showed that the procedure was feasible and safe. All five patients successfully received the implant, and the device functioned as intended. Most patients experienced only mild side effects, such as temporary tingling or minor discomfort, which did not require stopping the treatment. No serious complications arose from the surgery or the long-term use of the device. In terms of how well the treatment worked, the results were mixed, which is expected in a small group of patients with such a complex condition. One patient, in particular, showed a remarkable response. This individual, who had been struggling with severe joint pain and a separate, long-standing pain condition in their arm, saw their joint inflammation drop significantly. Their pain levels decreased so much that they were able to stop taking pain medication entirely. This patient also experienced a complete resolution of their arm pain, a condition that had been resistant to all other treatments for over a decade.
While this one patient had a dramatic improvement, the other four did not see the same level of change in their joint symptoms during the first three months of the study. However, the researchers did find clues in the blood that explained why the treatment might work for some people. In the patient who improved the most, the electrical stimulation appeared to change the behavior of specific immune cells. The levels of a protein called IL-17A, which drives inflammation, dropped significantly. At the same time, the activity of certain immune cells that usually cause damage was reduced. In contrast, the patients who did not improve did not show these changes in their blood markers. This suggests that the treatment might be most effective for a specific type of patient whose disease is driven by these particular immune pathways.
The study also revealed that the treatment could be adjusted to different schedules. Some patients received the electrical pulses only during the day, while others received them around the clock. All of these schedules were well tolerated, and the patients did not report that the nighttime pulses disturbed their sleep. One patient did experience a technical issue where the device stopped working properly after a few months, but this was a mechanical failure rather than a biological reaction, and the device was safely turned off without harming the patient. The researchers noted that for the patients who did not improve with the device alone, combining the stimulation with standard arthritis medication later in the study did lead to some improvement in disease activity, suggesting the two approaches might work well together.
This small study serves as a proof of concept. It demonstrates that it is possible to safely implant a device that stimulates the splenic nerve in humans and that this stimulation can, in some cases, calm the immune system enough to reduce the symptoms of rheumatoid arthritis. The fact that one patient saw their pain disappear completely and their joint inflammation drop to low levels offers a glimmer of hope for those who have run out of other options. However, because the group was so small, the researchers cannot yet say who will respond to the treatment or how often it will work. The findings suggest that this approach is safe and worth investigating further in larger groups of people to see if it can become a reliable new tool for managing difficult-to-treat arthritis.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.